Tech Company Financing Transactions
AnTolRx Funding Round
AnTolRx, based in Cambridge, secured $4 million from Pfizer Venture Investments, Orion Equity Partners and private investors.
Transaction Overview
Company Name
Announced On
9/9/2016
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series A
Investors
Pfizer Venture Investments (Lead Investor) (Michael Vincent)
Proceeds Purpose
We are grateful for the funding and support we have received from Pfizer, JDRF and Orion, as we continue to focus on developing disease-modifying therapies for patients with immune disorders, including type 1 diabetes, multiple sclerosis and inflammatory bowel disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 1400 West 14303
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
At AnTolRx we are approaching the treatment of autoimmune diseases differently--through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Carthy
Chief Scientific Officer
Francisco Quintana
Browse more venture capital transactions:
Prev: 9/8/2016: Callstats.io venture capital transaction
Next: 9/9/2016: Blackstorm venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs